WVE

WVE

USD

Wave Life Sciences Ltd. Ordinary Shares

$8.010+0.000 (0.000%)

リアルタイム価格

Healthcare
バイオテクノロジー
シンガポール

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$8.010

高値

$8.270

安値

$7.950

出来高

1.95M

企業ファンダメンタルズ

時価総額

1.3B

業種

バイオテクノロジー

Singapore

取引統計

平均出来高

2.52M

取引所

NGM

通貨

USD

52週レンジ

安値 $5.28現在値 $8.010高値 $16.74

関連ニュース

GlobeNewswire

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or

もっと見る
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
GlobeNewswire

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will

もっと見る
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
GlobeNewswire

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under "WVE-007 (GalNAc-siRNA)" – "Next steps."

もっと見る
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
GlobeNewswire

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well

もっと見る
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Analyst Upgrades

Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences with a Buy rating and announces Price Target of $22.

もっと見る
Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22